RxDoctor Payments DataLook up a doctor →

Michael Kurtz, DO

Sports Medicine · Garden Grove, CANPI 1194814020

Payments from drug & device makers

$251,649in general payments, 2019–2025

Across 999 payments — averaging $251.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$55K
  • Genentech, Inc.$47K
  • Bristol Myers Squibb$40K
  • Takeda Pharmaceuticals U.S.A., Inc.$31K
  • Gilead$29K
  • Bausch Health US, LLC$19K
  • plus $30K from 54 others
$10,237in research payments, 2019–2025

Across 7 payments — averaging $1462.48 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Bausch Health US, LLC$7K
  • AbbVie$2K
  • Eli Lilly$2K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)204$55,308
Genentech, Inc.9$47,310
Bristol Myers Squibb8$39,613
Takeda Pharmaceuticals U.S.A., Inc.38$31,238
Gilead7$29,086
Bausch Health US, LLC34$19,235
Pfizer66$17,624
Amgen(2 entities)124$1,732
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC86$1,412
Novo Nordisk81$1,361
Johnson & Johnson(3 entities)45$1,102
Lilly USA, LLC31$781
AstraZeneca29$714
Optinose US, Inc.21$605
Boehringer Ingelheim15$456
Antares Pharma, Inc.25$415
Eisai Inc.14$297
Amarin Pharma, Inc.18$285
Biohaven Pharmaceuticals, Inc.7$254
Jazz Pharmaceuticals Inc.7$253
Abbott13$229
Arbor Pharmaceuticals, Inc.9$186
Almatica Pharma LLC7$182
Novartis8$146
Scilex Pharmaceuticals Inc.6$122
GSK6$117
Regeneron Healthcare Solutions, Inc.1$99
Merck6$98
E.r. Squibb & Sons, L.L.C.4$77
Biohaven Pharmaceutical Holding Company Ltd.3$74
Halozyme Inc4$68
Impel Pharmaceuticals Inc.3$59
Sunovion Pharmaceuticals Inc.5$58
Currax Pharmaceuticals LLC3$55
Tris Pharma Inc3$51
Tolmar, Inc.3$51
Esperion Therapeutics, Inc.2$45
Sanofi Pasteur Inc.2$45
Mylan Specialty L.p.2$45
Dexcom, Inc.2$45
Phathom Pharmaceuticals, Inc.2$40
Astellas Pharma US Inc2$40
Verity Pharmaceuticals Inc.1$40
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)2$36
Adlon Therapeutics L.p.2$32
Krystal Biotech Inc1$32
IBSA Pharma Inc.2$31
Dynavax Technologies Corporation2$30
Teva Pharmaceuticals USA, Inc.2$30
Caris MPI, Inc.1$30
Assertio Therapeutics, Inc.2$27
Acerus Pharmaceuticals Corporation2$26
Aytu Biopharma, Inc.1$25
Azurity Pharmaceuticals, Inc.1$25
Bayer1$25
Boston Scientific1$24
Kowa Pharmaceuticals America, Inc.1$22
Noven Therapeutics, LLC1$21
Exact Sciences1$19
Sanofi-aventis U.S. LLC1$18

How this compares

$251,649 in reported general payments places this provider in the 90th percentile of 662 sports medicine providers in California.

See all sports medicine providers in California →

Medicare billing

Part B allowed, 2024
$429,456
Medicare patients
448
Services billed
8,453

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other sports medicine in Garden Grove

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →